0.9x. Total equity was at Bt83,486mn, decreasing -2.7%. Cash flow In 9M23, cash flow from operation (after tax) reported at Bt62,485mn, increasing 9.4% compared to 9M22 following an improvement in EBITDA
million (THB 8.4 billion), -7% YoY, Core EBITDA margin 10% Core Net profit after tax of $128 million (THB 4.0 billion), -27% YoY Core Earnings Per Share of THB 0.67, -32% YoY Operating Cash Flow of
Cash Flow of $261 million (THB 8.3 billion) Indorama Ventures 1st Quarter 2019 MD&A 2 1Q 2019 Summary Financials Table 1: Core Financials of Consolidated Business Quarterly Last Twelve Months $million
cash flow (“DCF”) and Guideline public company method (“GPCM”) when determine the fairness of valuation is reasonable to be between 1 : 5.44 and 1 : 5.92 (details as shown in attachment 1), therefore
0.99 0.69 0.64 55% 3.27 2.22 47% Reported EPS after PERP Interest (THB) 1.04 1.92 0.87 20% 4.15 3.21 29% Core EBITDA/ton ($) 140 111 100 40% 120 94 28% Operating Cash Flow 249 247 226 10% 941 827 14% Net
8.1% from Dec-20 due to an increase in retained earnings. Cash flow In FY21, Cash flow from operation reported Bt86,634mn increasing 1.2% YoY following EBITDA improvement. Total investing cash flow was
illness in Thais, especially heart disease, stroke, cancer and diabetes due partly to the increasing number of elderly; (iii) the increasing proportion of foreign patients coming for medical treatment in
trade accounts payable. and the company has a list of liabilities under the lease agreement. Coming into the financial statements this year According to the financial reporting standard No. 1 6 , it has
, especially heart disease, stroke, cancer and diabetes due partly to the increasing number of elderly; (iii) the increasing proportion of foreign patients coming for medical treatment in Thai hospitals due to